BACE2抗体;BACE2 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P12937(BACE2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

BACE2 (β-site amyloid precursor protein-cleaving enzyme 2) is a transmembrane aspartic protease closely related to BACE1. both involved in amyloid precursor protein (APP) processing. While BACE1 is a well-established therapeutic target for Alzheimer’s disease (AD) due to its role in generating neurotoxic β-amyloid peptides, BACE2 has dual, context-dependent functions. It can cleave APP at alternative sites, potentially reducing amyloid-β production, but also processes other substrates linked to metabolic disorders, including diabetes. BACE2 is highly expressed in pancreatic β-cells and regulates insulin secretion, with genetic variants associated with type 2 diabetes risk.

Antibodies targeting BACE2 are valuable tools for studying its expression, localization, and functional interplay with BACE1. They enable researchers to investigate tissue-specific roles, particularly in neurodegenerative and metabolic diseases. Therapeutic BACE2 antibodies are less advanced than BACE1 inhibitors but attract interest for their potential to modulate amyloid pathology without disrupting BACE1's physiological functions. Challenges include ensuring selectivity over BACE1 and optimizing blood-brain barrier penetration for AD applications. Recent studies also explore BACE2's role in cancer and Down syndrome, broadening its biomedical relevance. Commercial and custom BACE2 antibodies are widely used in immunoassays, Western blotting, and immunohistochemistry, supporting both basic research and drug development efforts.